Hemorrhagic Cystitis after Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: Protective Effect of MESNA Continuous Infusion
Authors:
Open Access
- 1 August 2020
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 26 (8) , 1492-1496
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global PerspectiveTransplantation and Cellular Therapy, 2009
- Cyclophosphamide and cancer: golden anniversaryNature Reviews Clinical Oncology, 2009
- HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation CyclophosphamideTransplantation and Cellular Therapy, 2008
- Competing risk analysis using R: an easy guide for cliniciansBone Marrow Transplantation, 2007
- Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCTBlood, 2005
- Clinical Pharmacokinetics of CyclophosphamideClinical Pharmacokinetics, 2005
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988
- The development of mesna for regional detoxificationCancer Treatment Reviews, 1983
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958